News

YM BioSciences (YM) has received a license from the US Department of the Treasury’s Office of Foreign Assets Control (OFAC), to further develop its lead product – nimotuzumab

Eiger BioPharmaceuticals has initiated patient dosing in CLEAN-1 clinical trial in patients chronically infected with the hepatitis C virus (HCV). The trial, undergoing in centers in Australia and

Patheon’s Manati solid dose manufacturing facility in Puerto Rico has received regulatory approval from the European Medicines Agency (EMEA), following the completion of inspection by the Medical Products

EMD Serono and the University of Texas M D Anderson Cancer Center have signed a three years strategic alliance. The deal is to provide M D Anderson with

AVI BioPharma has reported a revenue of $2.9m for the second quarter of 2009, a decrease when compared to $5.0m in the prior-year period. The company has reported

Depomed’s phase 1 pharmacokinetic study for DM-1992 has shown positive results, with an extended coverage above levodopa’s efficacious threshold and also extended the time to peak levodopa concentration

CytRx has reported a net loss of $2.2m, or $0.02 per share for the second quarter ended June 30, 2009, compared with a net loss of $5.8m, or

Mylan has received FDA approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan Succinate Tablets, 25mg, 50mg and 100mg. Mylan’s Sumatriptan Succinate Tablets are the generic version

Nycomed and Forest Laboratories (Forest) have signed an exclusive development, manufacturing and commercialisation agreement in the US for Daxas (roflumilast). Its a once-daily oral treatment for patients suffering